SCHEMBL3089109

SCHEMBL3089109

Nc1cc(CO)ccc1N1CCC(CO)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.43
GAA P10253 5/20 0.43
POLB P06746 3/20 0.43
HSD17B10 Q99714 3/20 0.43
NR4A1 P22736 1/20 0.43
ALDH1A1 P00352 6/20 0.40
MAPT P10636 2/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
CSF1R P07333 2/20 0.39
S100B P04271 1/20 0.38
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 2/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3081400 0.88 KDM4E (0.44) KDM4EGAAPOLBHSD17B10NR4A1
SCHEMBL3078172 0.88 CSF1R (0.41) KDM4EGAAPOLBHSD17B10NR4A1
SCHEMBL3073387 0.85 GAA (0.59) KDM4EGAAPOLBHSD17B10NR4A1
SCHEMBL357944 0.82 KDM4E (0.58) KDM4EGAAPOLBHSD17B10NR4A1
SCHEMBL29977999 0.82 KDM4E (0.58) KDM4EGAAPOLBHSD17B10NR4A1
SCHEMBL358763 0.81 S100B (0.59) KDM4EGAAPOLBHSD17B10NR4A1
SCHEMBL3089107 0.80 MAPT (0.47) KDM4EGAAHSD17B10ALDH1A1MAPT
SCHEMBL3096112 0.78 KMT2A (0.62) KDM4EGAAMAPTCSF1RMEN1
SCHEMBL14336200 0.77 KDM2B (0.41) KDM4EGAAPOLBHSD17B10ALDH1A1
SCHEMBL359961 0.74 KDM4E (0.51) KDM4EPOLBALDH1A1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7429603-B2 Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2008-09-30 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
US-7429603-B2 Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2008-09-30 US disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed
US-20050004112-A1 C-fms kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER KDM4E 1464/4885GAA 4492/4885POLB 4067/4885
US-20050004112-A1 C-fms kinase inhibitors FLT3, FGR, FER KDM4E 1258/4885GAA 4304/4885POLB 4110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.